Health Promotion Initiative

[stextbox id=”info”  collapsing=”false” collapsed=”false” direction=”ltr” float=”true” align=”right” width=”300″ color=”333333″ bcolor=”a7a8aa” bgcolor=”e0e0e0″ mleft=”15″ mright=”5″ mtop=”5″ mbottom=”15″  image=”null”] Get Involved

Act on your commitment by joining the Health Promotion Team; email now.

Initiative Co-Chairs          

  • Phil Edmundson, Chairman & CEO, William Gallagher Associates
  • Jack Manning, President and CEO, Boston Capital

Team Meetings

  • The Health Promotion Team meets regularly, with conference calls as needed.

To learn more about the team’s work and how you can get involved, contact Erica Levy, Program Director, at 617-401-239.


The Alliance believes that a healthy population and vibrant workforce is key to America’s quality of life and competitive future. In tackling the issue of health promotion, the Alliance’s immediate focus is to:

  • Promote health and wellness within our respective workforces and across the general population
  • Contain health care costs by changing the model for health care access and delivery, particularly by insuring all of our population and shifting costs from tertiary care to preventive and primary care
  • Promote innovation in health care and life sciences to create better health outcomes, more efficient and less-costly services, and job growth

Health and Wellness

The U.S. spends more than $2 trillion annually on health care, yet millions of Americans suffer from chronic diseases such as heart disease, stroke, cancer and diabetes. Simple efforts to improve nutrition, increase physical activity and prevent smoking could save the nation millions in terms of reduced health care costs and increased productivity. Alliance leaders are taking an active role in this area by:

  • Embracing health and wellness campaigns, tracking their ROI, and working with insurers to deliver savings based on those outcomes
  • Supporting funding for public health programs at the state and federal level
  • Working to eliminate perverse incentives such as the Massachusetts sugar tax exemption
  • Supporting various anti-smoking programs including a partnership with Tobacco Free Mass

Cost Containment 

The Affordable Care Act of 2010 stands to reduce the costs of health care nationally by increasing insurance market competition, aiding those who can’t afford coverage and moving toward valued payments for services that reward quality and efficiency over high volume.  But, the Supreme Court is considering challenges to the law, and its efficacy will be hotly debated during the Presidential election cycle. At the state level, where health care reform has been implemented, MA is under pressure to control the costs of covering all of its citizens to sustain the program in-state and to demonstrate to the country that universal insurance is affordable.

The Alliance supports full implementation of the Affordable Care Act, and encourages business leaders to educate their employees on their health care choices to help them become proactive customers of health care. At the state level, the Alliance supports changes that make our health care system more effective, efficient and sustainable.

Innovation in Health 

Jack Manning, co-chair of the Alliance Health Promotion Team, speaks at a March 2012 event.

Medical research is critical to the innovation economy, and it is one of the highest leverage investments we can make. The National Institutes of Health (NIH) currently supports 325,000 researchers at over 3,000 universities in the U.S.  In addition to clinical impact, each NIH dollar generates more than twice as much in state economic output, not including the jobs generated by the companies who are spun out of NIH funding. Yet, at $31 billion, NIH funding is low, roughly the same in constant dollars as it was ten years ago. At the same time, increased delays in the FDA approval process are stifling the pace of innovation and reducing America’s competitive advantage.

The Alliance supports increased and stable funding for National Institutes of Health (NIH), along with regulatory reform of the FDA and its approval process to support innovation in the pharmaceutical, biotech and medical device industries.